AstraZeneca’s AZD4076: Promising Developments in NASH Treatment

AstraZeneca (AZN) announced an update on their ongoing clinical study.

Study Overview: AstraZeneca’s recent clinical study, officially titled A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects, aimed to evaluate the safety and tolerability of AZD4076 in healthy male participants. This first-in-human study is significant as it explores potential treatments for Non-alcoholic Steatohepatitis (NASH), a condition with limited therapeutic options.

Intervention/Treatment: The study tested AZD4076, a drug administered subcutaneously in single ascending doses. The purpose was to assess its safety profile and pharmacokinetics compared to a placebo.

Study Design: The study was interventional, with a randomized allocation and a parallel intervention model. It was single-blind, meaning participants were unaware of whether they received AZD4076 or a placebo. The primary purpose was basic science, focusing on understanding the drug’s effects.

Study Timeline: The study began on November 17, 2015, and was completed with the last update submitted on November 18, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for data analysis and potential future developments.

Market Implications: The completion of this study could positively influence AstraZeneca’s stock performance by bolstering investor confidence in their pipeline for NASH treatments. As the pharmaceutical industry seeks effective NASH therapies, AstraZeneca’s progress in this area could position it favorably against competitors.

The study is completed, with further details available on the ClinicalTrials portal.

To learn more about AZN’s potential, visit the AstraZeneca drug pipeline page.